Recombinant, fully human, affordable therapy for hemophilia
Human: Cell Machines is an early-stage biotechnology company producing unique, recombinant therapeutic proteins sourced from non-embryonic human liver cell line. Our first products will be very long-acting factors for Hemophilia A and B.
Patented: Cell Machines uses a proprietary human liver cell-based technology platform and has a rich patent estate covering multiple aspects of our technology.
Imaginative: Cutting-edge protein design paired with breakthrough bioprocessing in our proprietary cellular microfactories.
Positioned: Cell Machines is singularly positioned to meet the demands of today’s hemophilia patients—creating affordable and accessible protein therapies to address a high unmet global need for on-demand or prophylactic treatment.
Cell Machines is CREATING:
- Long acting, critically needed protein therapies
- Transformative biosimilars for rare diseases
- Affordable, available products for people who need them most